IMG-025 ameliorates IgA nephropathy by inhibiting lectin-driven complement activation
April 6, 2023
Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is increasing evidence that the lectin-driven complement activation may be behind it. Mannose-binding lectin serine protease 2 (MASP-2) has been studied as a therapeutic target in the treatment of IgA nephropathy, as it is one of the main lectin pathway activators.